



Contact: Martin Nee  
(212) 841-7932  
[martin.nee@cushwake.com](mailto:martin.nee@cushwake.com)  
[www.twitter.com/cushwake](http://www.twitter.com/cushwake)

CUSHMAN & WAKEFIELD, INC.

DEPT. OF MARKETING & CORPORATE COMMUNICATIONS

FOR IMMEDIATE RELEASE

## **uniQure Signs 53,343 SF Lease for Pharmaceutical Manufacturing Facility in Lexington**

*-Dutch-based world leader in the research and early development of human gene based therapies to launch production facility in Greater Boston*

BOSTON – July 29, 2013 – Cushman & Wakefield today announced the completion of a 53,343 square foot office, laboratory and GMP manufacturing lease at 113 Hartwell Avenue in Lexington. Cushman & Wakefield Executive Directors Mark Winters and Richard Ruggiero represented the tenant, uniQure, in the transaction. The landlord is King Street Properties LLC.

“We are delighted to further expand uniQure’s operations with the opening of a world-class facility in the Boston area, which is one of the world’s leading destinations for life science entities”, said Philip Astley-Sparke, President of uniQure, U.S. “This new facility will enable us to provide strategic leadership in the industry and will help build uniQure’s clinical, regulatory, and commercial infrastructure in the U.S.”

Stephen Lynch, Principal of King Street Properties LLC, added: “The announcement that uniQure, a world leader in the life science industry, has selected Lexington for its regional base of operations speaks volumes about the quality and location of our facility. We look forward to supporting its presence in this market.”

uniQure’s 10-year lease at 113 Hartwell Avenue will enable the firm to set up a production facility commencing in April of 2014, which may eventually employ up to 50 professionals. The building is currently undergoing extensive base building and architectural improvements designed to transform the existing 103,000 square foot building into a state-of-the-art life science facility.

Based in Amsterdam, the Netherlands, uniQure’s lead product, Glybera, was developed for the treatment of lipoprotein lipase deficiency was approved by the European Commission in November 2012. Glybera is the first gene therapy approved in the Western world. uniQure has a product pipeline with several gene therapies: for hemophilia B, acute intermittent porphyria, Parkinson’s disease and Sanfilippo B. The company employs a staff with extensive

scientific and industry experience, and is the world leader in manufacturing of AAV-based products on a commercial scale, meeting cGMP requirements, and has extensive experience in the regulatory process for gene therapies.

\* \* \*

#### **About Cushman & Wakefield**

Cushman & Wakefield is the world's largest privately-held commercial real estate services firm. The company advises and represents clients on all aspects of property occupancy and investment, and has established a preeminent position in the world's major markets, as evidenced by its frequent involvement in many of the most significant property leases, sales and assignments. Founded in 1917, it has 253 offices in 60 countries and nearly 15,000 employees. It offers a complete range of services for all property types, including leasing, sales and acquisitions, equity, debt and structured finance, corporate finance and investment banking, corporate services, property management, facilities management, project management, consulting and appraisal. The firm has more than \$3.7 billion in assets under management globally. A recognized leader in local and global real estate research, the firm publishes its market information and studies online at [www.cushmanwakefield.com/knowledge](http://www.cushmanwakefield.com/knowledge).

For the New England area, Cushman & Wakefield maintains offices in Boston, Massachusetts; Manchester, New Hampshire; Hartford and Stamford, Connecticut; and Portland, Maine. To find out more about Cushman & Wakefield, please call 617.330.6966.

# # #